Ivermectin does not reduce risk of COVID-19 hospitalization, clinical study shows
A clinical trial, conducted by a partnership between academics and clinicians in Brazil and Canada, found that anti-parasitic drug ivermectin does not reduce the risk of hospitalization for patients with COVID-19.
The peer-reviewed study also showed ivermectin treatment did not help with various other health measures related to the virus such as viral clearance after a week, speed of recovery or risk of death. The study results were published in the New England Journal of Medicine (NEJM).
It don’t do JACK.
A clinical trial, conducted by a partnership between academics and clinicians in Brazil and Canada, found that anti-parasitic drug ivermectin does not reduce the risk of hospitalization for patients with COVID-19.
The peer-reviewed study also showed ivermectin treatment did not help with various other health measures related to the virus such as viral clearance after a week, speed of recovery or risk of death. The study results were published in the New England Journal of Medicine (NEJM).
It don’t do JACK.